- Molecular NameRisedronate
- SynonymNE-58095; risedronate; Risedronate sodium; Risedronic acid
- Weight283.113
- Drugbank_IDDB00884
- ACS_NO105462-24-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-4.11
- pka1.35; 2.87; 7.03; 11.3
- LogD (pH=7, predicted)-8.34
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)0.55
- LogSw (predicted, AB/LogsW2.0)822.16
- Sw (mg/ml) (predicted, ACD/Labs)111.56
- No.of HBond Donors5
- No.of HBond Acceptors8
- No.of Rotatable Bonds4
- TPSA167.8
- StatusFDA approved
- AdministrationN/A
- PharmacologyA bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.
- Absorption_valueN/A
- Absorption (description)Rapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract
- Caco_2N/A
- Bioavailability65.0
- Protein binding24.0
- Volume of distribution (VD)6.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNone
- Half life200 h (Exhibits multi-exponential elimination. The plasma t1/2 for the first and second exponential phases is 0.9 and 13 hours, respectively. The longer terminal t1/2 reported is thought to represent dissociation of risedronate from the surface of bone)
- ExcretionRenal and fecal
- Urinary Excretion87
- Clerance1.5 ml/min/kg
- ToxicitySide effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness.
- LD50 (rat)N/A
- LD50 (mouse)N/A